中国中药(00570.HK)续涨近7%曾见4.89元 获委托产改善新冠肺炎症状中药制剂
中国中药(00570.HK)获委托生产改善新冠肺炎症状中药制剂,该股六连涨,今早升破上月所创高位4.46元,最多急涨15%高见4.89元,创近十个月高,现造4.53元,续涨6.8%,成交增至6,107万股,涉资2.84亿元。
该公司公布,广州市第八人民医院的医院中药制剂透解祛瘟颗粒通过广东省医疗机构传统中药制剂应急审批备案,并委托公司旗下子公司广东一方进行生产配制。公司指,该透解祛瘟颗粒能够明显改善新型冠状病毒感染肺炎(轻症)临床症状,有减少重型肺炎发生趋势,具有较好临床价值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.